8-K: Pulse Biosciences Appoints Jon Skinner as Chief Financial Officer

Pulse Biosciences appoints Jon Skinner as CFO, effective February 3, 2025, to support operational excellence and commercialization of the CellFX nanosecond PFA Platform.

Summary

• Pulse Biosciences has appointed Jon Skinner as Chief Financial Officer, effective February 3, 2025.
• Skinner's employment agreement includes an annual base salary of $400,000 and eligibility for an annual target bonus of 50% of his base salary.
• He will also receive a sign-on bonus of up to $56,000.
• Skinner was granted a stock option to purchase 300,000 shares of the company's common stock at an exercise price of $20.93 per share.
• 50% of the option shares will vest over four years, and the remaining 50% will vest upon achievement of market capitalization and revenue milestones.
• The company's market capitalization milestones range from $2 billion to $5 billion, and revenue milestones range from $8 million to $175 million.
• Skinner's employment is at-will, and he is eligible to participate in employee benefit plans.
• The company will reimburse Skinner for up to $56,000 to cover clawback compensation he repays to his former employer and any related taxes.
• If Skinner voluntarily resigns without Good Reason or is terminated for Cause within the first 24 months of employment, he must repay the sign-on bonus.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the appointment of a new CFO and the potential for growth. The terms of the employment agreement are reasonable and incentivize the CFO to contribute to the company's success. However, there are some risks associated with achieving the performance milestones and the at-will employment arrangement.

Positives

• Pulse Biosciences has appointed an experienced financial leader as its CFO.
• Jon Skinner has a strong background in finance and corporate development, with experience in both growth-stage and public companies.
• The employment agreement includes a sign-on bonus and stock options, incentivizing Skinner to contribute to the company's success.
• The performance-based vesting of stock options aligns Skinner's interests with those of the shareholders.
• The severance package provides Skinner with financial security in the event of an involuntary termination.

Negatives

• If Skinner voluntarily resigns without Good Reason or is terminated for Cause within the first 24 months of employment, he must repay the sign-on bonus.
• The vesting of a portion of the stock options is contingent upon achieving ambitious market capitalization and revenue milestones, which may be challenging to reach.

Risks

• The company's ability to achieve the market capitalization and revenue milestones required for Skinner's stock options to vest is uncertain.
• The at-will employment arrangement means that Skinner's employment can be terminated at any time, with or without cause.
• The company's financial performance could be negatively impacted if Skinner is unable to effectively manage the company's finances.

Future Outlook

The company expects Skinner's experience to be valuable in advancing its nanosecond PFA technology platform and scaling commercialization and operations.

Management Comments

• Paul LaViolette, Pulse Biosciences Co-Chairman and CEO, stated that Skinner's experience will be extremely valuable in advancing the nanosecond PFA technology platform.
• Jon Skinner stated that he believes nanosecond PFA will be a disruptive catalyst to advance the treatment of several disease states representing very large markets.

Industry Context

Pulse Biosciences is operating in the bioelectric medicine space, focusing on nanosecond pulsed field ablation (nsPFA) technology. The appointment of a CFO with experience in medical technology and M&A suggests the company is preparing for potential growth and strategic transactions.

Comparison to Industry Standards

• The compensation package for Jon Skinner, including base salary, bonus potential, and stock options, appears to be competitive with those offered to CFOs in similar-sized medical technology companies.
• The performance-based vesting of stock options is a common practice in the industry to align executive compensation with company performance.
• The market capitalization and revenue milestones for vesting are ambitious but not uncommon for growth-stage companies in the medical technology sector.
• Teleflex (NYSE: TFX) is mentioned as a previous employer of Mr. Skinner, providing a benchmark for the type of company he has experience with.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO as a positive development, potentially leading to improved financial performance and strategic decision-making.
• Employees may benefit from Skinner's leadership and expertise, potentially leading to improved operational efficiency and growth opportunities.
• Customers may benefit from the company's continued development and commercialization of its CellFX nanosecond PFA technology.
• The appointment of a CFO does not have a direct impact on suppliers or creditors.

Next Steps

• Jon Skinner will assume his responsibilities as CFO, overseeing the financial function and implementing financial strategies.
• The Board will set annual designated corporate goals and milestones for Skinner's annual bonus.
• The company will work towards achieving the market capitalization and revenue milestones required for Skinner's stock options to vest.
• The company will continue to develop and commercialize its CellFX nanosecond PFA technology.

Key Dates

Keywords

Chief Financial Officer, CFO, Jon Skinner, Pulse Biosciences, Employment Agreement, Stock Options, Severance, Nanosecond PFA, CellFX, Appointment